ValiRx Advances Women's Health and Oncology Pipeline with Focus on Triple-Negative Breast Cancer

Proactive - Interviews for investors

ValiRX CEO Dr Mark Eccleston joined Steve Darling from Proactive to discuss the company’s innovative approach to tackling women’s health and oncology challenges. Dr. Eccleston highlighted ValiRx’s collaboration with King’s College London through the Cytolytix joint venture, focusing on developing treatments for triple-negative breast cancer, one of the most aggressive and hard-to-treat forms of the disease. ValiRx adopts a unique model of evaluating and in-licensing promising assets from universities and small pharma companies. This approach enables the company to prioritize science with strong commercial potential, ensuring that innovative discoveries make their way into clinical development. A key asset in development is Cytolytix, a cytolytic peptide that selectively targets cancer cells by creating perforations in their membranes. This novel mechanism not only makes Cytolytix highly specific but also opens the door for its use in combination therapies and immuno-oncology partnerships, potentially revolutionizing cancer treatment. Looking ahead to 2025, Dr. Eccleston outlined plans to advance Cytolytix through preclinical pathways, evaluate three active programs, and expand the pipeline with new assets. In addition, legacy projects such as VAL201 and VAL401 continue to progress, with licensing deals and partnerships, including one with TheoremRx, further solidifying the company’s diverse pipeline. ValiRx remains steadfast in its mission to develop transformative therapies for unmet medical needs, with 2025 poised to be a critical year for clinical advancements and strategic growth. Stay tuned for updates as the company builds momentum in its pursuit of innovative cancer treatments. #proactiveinvestors #valirxplc #aim #val201 #CancerResearch #TripleNegativeBreastCancer #OncologyInnovation #Cytolytix #PharmaPipeline #WomensHealth #CancerTherapy #Biotech #ProactiveInvestors